A significant sized upside is ahead for the company
Now that the mechanism of action has been heavily confirmed already by AGN and NYR pre clinical studies, NYR will be the only drug in the world completing phase 1 for both stroke and traumatic brain injury leading into phase 2 for both. 100 billion dollar plus market potential on both conditions and says a lot of what’s to come once the remaining GLP results are out shortly and they dose the first humans next quarter.
Looking forward to the updated webinar this week where the CEO is talking on non dilutive funding after phase 1 is completed.
Ann: Brain Injury Program GLP Studies Further Update, page-28
Add NYR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.0¢ |
Change
0.013(14.9%) |
Mkt cap ! $20.04M | |||
| Open | High | Low | Value | Volume |
| 8.8¢ | 11.5¢ | 8.8¢ | $267.3K | 2.625M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 170097 | 10.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 11.0¢ | 208703 | 4 |
View Market Depth
| Last trade - 13.51pm 03/10/2024 (20 minute delay) ? |
| NYR (ASX) Chart |